Welcome, Guest. Please login or register.
September 30, 2022, 11:54:35 am

Login with username, password and session length

  • Total Members: 36692
  • Latest: maxiim
  • Total Posts: 766150
  • Total Topics: 65355
  • Online Today: 129
  • Online Ever: 5484
  • (June 18, 2021, 11:15:29 pm)
Users Online
Users: 1
Guests: 83
Total: 84


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Further Studies Confirm Effectiveness of Injectable PrEP for Women  (Read 1078 times)

0 Members and 1 Guest are viewing this topic.

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 19,483
  • Twitter @JimAllenDublin
    • HIV Lessons
Decent results for PrEP & Injectable PrEP for women  :)

In full:

In short:
Further Studies Confirm Effectiveness of Injectable Cabotegravir PrEP for Women

Injectable cabotegravir administered every other month is a highly effective pre-exposure prophylaxis (PrEP) option for women, according to two studies presented at the 11th International AIDS Society Conference on HIV Science (IAS 2021).

The HPTN 084 trial compared the safety and effectiveness of every-other-month injections of cabotegravir versus daily oral Truvada (tenofovir disoproxil fumarate/emtricitabine) in more than 3,000 cisgender women in sub-Saharan Africa. The parallel HPTN 083 study enrolled more than 4,000 gay and bisexual cisgender men and transgender women who have sex with men.

There were just four new cases of HIV among women who used cabotegravir (an annual incidence of 0.21%), compared with 34 among those who used Truvada (an annual incidence of 1.79%). In HPTN 083, cabotegravir injections reduced the risk of infection by 66% compared with Truvada.

But the long-acting injections may be even more effective for women than previously reported.

In the Truvada group, all but one of the women who acquired HIV had poor or inconsistent adherence around the time they tested positive, as shown by pill counts and measurement of tenofovir drug levels. Several of them showed evidence of drug resistance mutations.

In the cabotegravir group, two of the HIV-positive women never actually received the injections (one never showed up for her first injection visit and the other switched to Truvada when she became pregnant). A third woman missed or delayed several injections and had not received a shot for 16 weeks before she tested positive.

The fourth woman already had HIV when she enrolled in the study, retrospective testing showed.

After reclassifying the woman who already had HIV, the revised incidence was 0.15% for the cabotegravir group and 1.85% for the Truvada group, reflecting a 92% risk reduction.
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP


Terms of Membership for these forums

© 2022 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.